Browse Reports

BioRestorative Therapies, Inc. develops cell and tissue-based therapeutic products using adult stem cells. The company’s primary focus is on its Disc/Spine Program, with BRTX-100 as the lead investigational product designed for non-surgical treatment of chronic lower back pain arising from degenerative disc disease. BRTX-100 is an autologous mesenchymal stem cell product cultured under hypoxic conditions to enhance cell viability and is administered via injection into the damaged disc. The company is conducting a Phase 2 clinical trial with 99 patients enrolled and has FDA clearance for additional indications. BioRestorative also develops the ThermoStem Program targeting metabolic disorders using brown adipose derived stem cells and operates a commercial biocosmeceutical platform producing a proprietary cell-based serum for cosmetic use. The company has licensed a curved needle delivery device pending regulatory approval. BioRestorative has not generated significant revenues and funds operations through equity offerings and warrant exercises. As of March 31, 2026, the company held $3.1 million in cash and equivalents and reported a net loss of $2.15 million for the quarter.

Cenntro Inc. operates as a holding company with subsidiaries engaged in the design, manufacture, distribution, and servicing of electric and hydrogen-powered commercial vehicles. The company offers multiple vehicle series including Metro®, Logistar™, iChassis™, Avantier™, Teemak™, Bison Motor™, and Antric One. It employs an asset-light, distributed manufacturing model producing vehicle kits primarily in China for local assembly globally, supplemented by OEM partnerships. The company has developed a programmable smart chassis platform (iChassis™) for autonomous vehicle applications and is expanding into hydrogen-powered heavy-duty vehicles. Distribution has evolved from reliance on third-party channel partners to a hybrid model combining company-operated EV Centers, local dealer networks, and channel partners tailored to regional market conditions. Cenntro supports its distribution with a cloud-based parts distribution system and maintains warehouses in China, Spain, and the US. The company operates globally with subsidiaries in the US, Australia, Europe, Mexico, Hong Kong, Dominican Republic, and China. Financially, Cenntro reported a net loss and negative EPS for Q1 2026, with liquidity ratios indicating moderate short-term financial stability. The company faces competitive market dynamics, regulatory and legal risks, and challenges related to capital requirements and supply chain localization.

Autolus Therapeutics plc develops and commercializes programmed T cell therapies using proprietary modular technologies to engineer targeted and controlled CAR T cell products. The company’s lead product, AUCATZYL (obe-cel), is approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the US and UK, with commercial launches in both markets. The company’s pipeline includes programs targeting hematological cancers, solid tumors, and autoimmune diseases such as lupus nephritis and multiple sclerosis. Autolus employs advanced targeting technologies including fast off-rate CARs, dual-targeting CARs, and pharmacological safety switches to enhance efficacy and safety. Manufacturing is conducted at the Nucleus facility in the UK, with commercial distribution partnerships in the US. The company has incurred significant operating losses since inception and continues to invest heavily in clinical development and commercialization activities.

AleAnna, Inc. operates primarily in Italy, focusing on delivering natural gas supplies to Europe through onshore conventional natural gas exploration and renewable natural gas development. The company holds a significant working interest in the Longanesi field, one of Italy's largest modern natural gas discoveries, and owns additional conventional natural gas properties and exploration prospects supported by proprietary 3D seismic imaging. AleAnna has developed a renewable natural gas business targeting carbon negative biomethane production from agricultural waste, acquiring several biogas plants in Italy. The company is headquartered in Dallas, Texas, with offices in Rome and Milan, and is listed on NASDAQ under the ticker ANNA following a business combination in December 2024.

Fortress Biotech, Inc. is a biopharmaceutical company that operates through a network of subsidiaries and partner companies engaged in the development and commercialization of pharmaceutical products across various therapeutic areas. The company supports its subsidiaries with business, scientific, regulatory, legal, and financial expertise to advance product candidates and commercial products. Key subsidiaries include Journey Medical Corporation, Mustang Bio, Avenue Therapeutics, and Cyprium Therapeutics, among others. Fortress Biotech’s revenue is primarily generated through its subsidiaries’ product sales and collaboration agreements. The company’s business model includes strategic licensing, milestone payments, and equity financings to fund research and development and commercialization efforts. Fortress Biotech also manages debt facilities and maintains liquidity to support ongoing operations and growth initiatives.

Trailblazer Acquisition Corp. is a Cayman Islands exempted blank check company (SPAC) incorporated in June 2025. Its sole business purpose is to identify and complete an initial business combination with one or more target companies, primarily in the media and communications, sports and entertainment, technology, and consumer retail sectors. The company completed its IPO in September 2025, raising $275 million, which is held in a trust account to fund the business combination. The company has not yet selected a target and has no operating revenues. Its management team brings experience in operations, financing, and investing across multiple industries. The company must complete its business combination by September 2027 or liquidate and return funds to shareholders. The acquisition strategy targets companies with strong market positions, growth potential, and public market readiness.

Archimedes Tech SPAC Partners III Co. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. It completed its initial public offering in January 2026, issuing units consisting of ordinary shares and redeemable warrants. The company raised gross proceeds of $276 million, which are held in a trust account for the benefit of public shareholders. The company is classified as an emerging growth company and trades on The Nasdaq Stock Market under the symbols ARCI (ordinary shares), ARCIU (units), and ARCIW (warrants). As of March 31, 2026, the company reported strong liquidity with a current ratio of 14.84 and net income of approximately $1.57 million for the quarter. The company has undergone recent management changes with a new CEO appointed in April 2026.

Talon Capital Corp. is a Cayman Islands exempted company that went public in September 2025 through an initial public offering of units on The Nasdaq Stock Market. Each unit includes one Class A ordinary share and one-third of a redeemable warrant. The company raised gross proceeds of approximately $249 million, which are held in a trust account for the benefit of public shareholders until the completion of an initial business combination or other redemption events. The company operates under an administrative services agreement with its Sponsor, which provides office space and support services. Financial disclosures indicate the company is in an early stage with limited operational revenue but reported net income and strong liquidity as of the first quarter of 2026. Risk factors are disclosed primarily through the IPO prospectus and annual report, with no material changes reported recently.

Heartflow, Inc. operates in the healthcare technology sector, focusing on AI-driven diagnostic solutions for coronary artery disease (CAD). The company’s Heartflow Platform enhances coronary computed tomography angiography (CCTA) scans by applying advanced AI and computational fluid dynamics to create personalized 3D models of patients’ coronary arteries. This enables precise assessment of blood flow, stenosis, and plaque characteristics, which are critical for accurate diagnosis and treatment planning. Heartflow’s product suite includes Heartflow RoadMap Analysis, Heartflow FFR CT Analysis (the flagship product), Heartflow Plaque Analysis, and the upcoming Heartflow PCI Navigator. The platform is integrated into clinical workflows and reimbursed under established CPT codes, facilitating adoption. The company has a substantial data asset of over 160 million annotated CCTA images, supporting continuous algorithm improvement. Heartflow’s business model is primarily pay-per-click, billing customers when physicians order specific analyses. The company has an installed base of over 1,465 accounts in the US and is expanding its market presence. Despite strong clinical validation and guideline support, Heartflow has incurred significant net losses as it invests in growth and commercialization.

Terrestrial Energy Inc. is a holding company operating through its subsidiary Terrestrial Energy Development Inc., focused on commercializing its proprietary Integral Molten Salt Reactor (IMSR) technology, an advanced nuclear reactor design. The company completed a business combination with HCM II Acquisition Corp. in October 2025 and began trading on Nasdaq under the ticker IMSR. It participates in U.S. Department of Energy programs aimed at fast-tracking licensing and deployment of advanced nuclear reactors, including pilot projects for reactor construction and fuel production using standard assay low enriched uranium (SALEU) fuel. The company has no reported revenue for 2025, reflecting its development-stage status, and incurs significant research and development and general administrative expenses as it advances its technology and commercialization efforts.

Sutro Biopharma operates as a clinical-stage biotechnology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) for oncology indications. The company leverages its proprietary XpressCF® and XpressCF+® platforms, which enable rapid and precise protein synthesis and site-specific conjugation of cytotoxic payloads to antibodies. Sutro’s lead product candidate, STRO-004, targets tissue factor (TF) and is in Phase 1 clinical trials for multiple solid tumors. The company also has preclinical programs including STRO-006 and STRO-227, targeting integrin alpha v beta 6 and PTK7 respectively, with IND filings anticipated. Sutro has established collaborations with pharmaceutical companies such as Astellas, Merck, BMS, and EMD Serono, generating significant payments and advancing development candidates. The company’s strategy includes advancing clinical development, expanding its pipeline, and pursuing strategic partnerships to maximize value. Financially, Sutro reported a net loss in Q1 2026 but maintains strong liquidity with a current ratio above 3.0. The company faces competition from other ADC developers and established oncology therapeutics but aims to differentiate through its proprietary platform technology and homogeneous ADC products.

KinderCare Learning Companies, Inc. is a provider of childcare and early education services. The company operates centers that serve families, with revenue streams partially supported by federal, state, and local government programs offering tuition subsidies and other assistance. The business model involves managing childcare centers and delivering educational programs to children. The company faces operational risks related to government funding availability and regulatory changes. Leadership transitioned in late 2025 with the appointment of a new CEO and Chair. Financial disclosures indicate recent net losses and liquidity challenges as of early 2026. The company maintains incentive plans for employees and executives to drive performance.

Marblegate Capital Corp is a publicly traded holding company focused on the New York City regulated taxi medallion market. It operates through subsidiaries that manage a large portfolio of medallion-backed loans and operate the largest taxi fleet in NYC via Signal Taxi. The company generates revenue primarily from interest income on loans, leasing of vehicles and medallions to licensed drivers, consulting services, and fees related to loan restructuring and settlements. The business model centers on the taxi medallion as a scarce, municipally regulated asset critical to NYC's mobility infrastructure. Marblegate's operations include specialty finance and fleet operations segments, with significant recent growth in fleet operations following acquisitions and consulting agreements. The company became publicly traded on the OTCQX market in April 2025 and has incurred increased expenses related to public company status and business combination activities.

SpyGlass Pharma, Inc. focuses on developing long-acting, sustained drug delivery systems for chronic eye conditions. Its lead candidate, the BIM-IOL System, combines proprietary drug pads with an intraocular lens to deliver bimatoprost over three years, aiming to reduce intraocular pressure in patients undergoing cataract surgery who have open-angle glaucoma or ocular hypertension. The company is conducting Phase 1/2 and two registrational Phase 3 clinical trials, with enrollment expected to complete in 2027. SpyGlass Pharma has no approved products or revenues and has incurred significant losses since inception. It completed its IPO in February 2026, raising $172.5 million, and as of March 31, 2026, held $238.9 million in cash and equivalents. The company depends heavily on the success of the BIM-IOL System and faces risks related to clinical development, regulatory approval, manufacturing, intellectual property, competition, and capital requirements.

Bitcoin Infrastructure Acquisition Corp Ltd is a publicly listed company trading under the ticker BIXI. The company has not publicly disclosed detailed information about its sector, industry, or business operations in the available SEC filings. The latest quarterly filing indicates the company maintains strong liquidity and reported positive net income for the quarter ending March 31, 2026.

Synlogic, Inc. operates as a biotechnology company incorporated in Delaware with principal offices in Massachusetts. The company is governed by a four-member independent board of directors and maintains standard corporate governance policies including audit and compensation committees. As of the latest quarter ending March 31, 2026, Synlogic reported no revenue but a net income of $681,000 and holds strong liquidity positions. The company has a limited number of employees focused on strategic initiatives. Synlogic's common stock is no longer listed on Nasdaq but remains a reporting company under the Securities Exchange Act. The company has equity incentive plans in place and has engaged in strategic alternatives to enhance stockholder value.

LaFayette Acquisition Corp. is a Cayman Islands exempted special purpose acquisition company (SPAC) formed in June 2024 to effect a business combination through merger, share exchange, asset acquisition, or similar transaction. The company completed its IPO on October 27, 2025, issuing 11.5 million units at $10 each, raising gross proceeds of $115 million, plus a private placement of 380,000 units raising $3.8 million. The net proceeds are held in a trust account until a business combination or liquidation event. The company has not commenced operations and currently earns interest income on trust account securities. Its management team includes experienced professionals with backgrounds in investment banking, private equity, and SPAC governance. The company intends to identify and complete a business combination with a target company that aligns with its management's expertise, focusing on companies with strong management, market readiness, sound financials, and defensible market positions, typically with enterprise values between $500 million and $1.5 billion.

Oncolytics Biotech Inc is focused on developing pelareorep, an intravenously delivered oncolytic reovirus immunotherapy that selectively infects and replicates in RAS-mutated cancer cells. Pelareorep acts by modifying the tumor microenvironment to enhance innate and adaptive immune responses, making tumors more susceptible to a range of cancer treatments including chemotherapy, checkpoint inhibitors, and other immuno-oncology agents. The company has conducted extensive clinical trials involving over 1,600 patients, showing encouraging efficacy signals in pancreatic, anal, colorectal, and breast cancers. Pelareorep is generally well tolerated with manageable side effects. The company holds a substantial patent portfolio protecting pelareorep and related technologies, with patent rights extending into the 2030s and beyond through pending applications. Oncolytics Biotech's strategy includes advancing pelareorep through clinical development, regulatory approval, and strategic partnerships, with a focus on gastrointestinal cancers. The company has not yet achieved profitability and relies on capital markets to fund operations. As of March 31, 2026, it reported cash and equivalents of $5.493 million and a current ratio of 1.38, indicating liquidity for near-term milestones but requiring additional financing for longer-term plans. The company faces competition from multiple cancer therapy modalities and depends on successful clinical, regulatory, and commercial execution.

P3 Health Partners Inc. is a Delaware-incorporated population health management company that completed a business combination in December 2021, resulting in an Up-C structure with P3 Health Partners Inc. as sole manager and partial owner of P3 Health Group, LLC. The company focuses on delivering value-based care primarily in the Medicare Advantage market, which covers approximately 34 million Medicare eligible lives in 2025. P3 contracts with health plans to provide capitated care services, receiving per-member-per-month payments and managing total cost of care to improve clinical outcomes and reduce healthcare spending. The company’s P3 Care Model emphasizes patient centricity, physician leadership, and a delegated care model that leverages local physician networks via an affiliate model, preserving physician independence and existing patient relationships. P3 supplements these partnerships with employed primary care physicians and operates clinics and wellness centers. Its proprietary technology platform integrates clinical and claims data to risk stratify patients and provide actionable insights to physicians. The company had contracted with approximately 2,400 primary care physicians as of December 31, 2025, representing less than 1% of U.S. PCPs, indicating significant market opportunity. P3’s revenue is primarily capitated revenue from at-risk contracts with health plans, with four health plans accounting for approximately 75% of total revenue in 2025. The company operates in a highly competitive and fragmented healthcare industry, facing competition from traditional fee-for-service models and other population health management companies. P3’s growth strategy includes expanding membership through current payor relationships, geographic expansion, and accretive acquisitions.

Big Digital Energy, Inc. (formerly Mawson Infrastructure Group Inc.) is a U.S.-based technology company specializing in digital infrastructure platforms. Its operations span four main business areas: Digital Colocation, AI and HPC Colocation, Energy Management, and Digital Assets Mining. The company operates data centers with a total capacity of approximately 129 MW located in the Pennsylvania-New Jersey-Maryland Interconnection Energy Market (PJM Energy Market), one of North America's largest wholesale power markets. It focuses on using carbon-free energy sources, including nuclear power, to support sustainable growth in digital economy applications. The company provides colocation services to enterprise customers, hosting specialized computing equipment for digital asset mining and AI/HPC workloads, with revenue generated through fee-based and profit-sharing agreements. It also operates its own Bitcoin mining operations and participates in energy management programs to optimize energy costs and grid stability. The company faces risks related to customer concentration, supply chain constraints, regulatory changes, and market volatility. Recent strategic moves include a joint mining agreement with an affiliate to deploy mining hardware and optimize facility utilization [S1][S2].

Alaska Silver Corp., incorporated in British Columbia in 2020, operates in the mineral exploration and development sector with a focus on Alaskan properties such as Illinois Creek, Round Top, and Honker. The company consolidates its operations through wholly owned subsidiaries in the USA. It is publicly traded on the TSX Venture Exchange under the symbol 'WAM'. The company’s financials as of March 31, 2026, show cash and equivalents of approximately $6.4 million USD and a current ratio of 1.44, indicating liquidity to support ongoing operations. Recent activities include a significant drill program at Illinois Creek and successful capital raises through offerings. The company’s financial statements comply with US GAAP and SEC regulations, and management highlights the need for further financing to continue development and exploration activities.

Transportation & Logistics Systems, Inc. is a publicly traded holding company currently without operating business, classified as a shell company. The company ceased operations in the first quarter of 2024 due to lack of capital and insolvency of subsidiaries. It is pursuing a restructuring strategy and exploring new business opportunities, including a planned acquisition of Patriot Glass Solutions, LLC, which specializes in automotive and commercial window tinting and proprietary glass strengthening technologies. The acquisition is intended to provide a profitable platform and expand TLSS's presence in the safety and security technology industry. The company faces significant financial and operational risks, including liquidity constraints, recurring losses, dilution from convertible preferred stock, and dependence on a sole executive officer. TLSS has material weaknesses in internal controls and limited management depth, impacting its ability to report financial results timely and accurately.

Sharps Technology Inc. is a medical device sales and distribution company specializing in syringe products and related drug-delivery systems. The company markets to healthcare providers and medical supply organizations in domestic and international markets. It has transitioned from manufacturing to primarily marketing existing inventory and plans to expand its distribution platform by representing third-party manufacturers of complementary medical products. Sharps Technology has adopted a digital asset treasury strategy focused on accumulating and staking Solana (SOL) cryptocurrency, which constitutes the majority of its treasury assets. The treasury strategy includes staking SOL to earn rewards, use of derivatives for hedging and yield enhancement, and maintaining liquidity with cash and stablecoins. The company has established governance and risk controls overseen by a Treasury Oversight Committee and the Board. Recent operational milestones include the commencement of commercial shipments of smart safety syringes and multiple capital raising activities to support growth and treasury expansion.

TMC the metals Co Inc. develops polymetallic nodules from the deep seabed in the Clarion Clipperton Zone, a large submarine fracture zone in the Eastern Pacific Ocean. These nodules contain critical metals essential for strategic sectors such as semiconductors, energy infrastructure, defense, and batteries. The company aims to establish a sustainable metal supply chain by collecting nodules offshore and processing them onshore, primarily under U.S. regulatory frameworks. TMC holds significant mineral resources and has submitted consolidated exploration and commercial recovery permit applications to NOAA. The company collaborates with leading partners for offshore collection system development, onshore processing feasibility, and refining technologies. TMC is currently in the development phase, with pilot systems tested and feasibility studies completed. It plans phased production ramp-up contingent on regulatory approvals and financing.

Royalty Management Holding Corp (RMHC) was formed as a blank check company in 2021 to pursue business combinations. It consummated a merger with Royalty Management Corporation in October 2023, becoming a royalty company focused on acquiring and structuring cash flow streams from assets primarily in natural resources sectors such as energy, critical minerals, infrastructure materials, and related technologies. The company’s business model involves monetizing existing cash flow streams and identifying transitionary cash flows for future growth. RMHC’s investments include intellectual property, real estate, permits, mining properties, and service businesses supporting infrastructure expansion. The company changed its incorporation from Delaware to Florida in 2025. Revenues have increased notably due to new contracts in its environmental services subsidiary, though the company reported net losses in recent quarters. Liquidity metrics as of March 2026 show a current ratio of 1.21 and cash ratio of 0.16, reflecting moderate short-term financial health. The company faces risks related to its short operating history, concentration of revenue sources, management experience, and potential dilution from equity issuances.

Propanc Biopharma, Inc. is focused on developing PRP, a patented pancreatic proenzyme formulation combining trypsinogen and chymotrypsinogen, designed to inhibit tumor growth and metastasis by targeting cancer stem cells and promoting differentiation therapy. PRP has received Orphan Drug Designation from the FDA for pancreatic cancer. The company has completed preclinical studies and is advancing toward clinical trials, with a Phase Ib study planned for late 2026 subject to financing. Propanc operates primarily through outsourcing R&D and manufacturing activities and collaborates with academic institutions for synthetic proenzyme development. The company is pre-revenue and relies on financing to fund clinical development and operations. Recent corporate actions include a 1-for-25 reverse stock split to meet Nasdaq listing requirements and multiple provisional patent applications to strengthen intellectual property protection globally.

Tivic Health Systems, Inc. operates in the healthcare sector, developing medical devices and biopharmaceutical products. Its portfolio includes Vagus Nerve Stimulation (VNS) technology and ClearUP 2.0, a device for sinus pain relief. The company has expanded into drug development through acquisition of exclusive rights to Entolimod, a Phase III TLR5 agonist from Statera Biopharma. Financially, the company is in an early growth stage with limited revenue and ongoing net losses. It maintains a strong liquidity position with cash and current assets exceeding current liabilities by over three times as of Q1 2026. The company recently changed its corporate name to Valion Bio, Inc. and its ticker symbol to VBIO, reflecting a possible strategic repositioning. Management oversees cybersecurity risks with regular board oversight. The company is classified as an emerging growth company and continues to disclose risks consistent with prior reports.

NexGel, Inc. operates in the regenerative biomaterials sector, focusing on the acquisition, licensing, and commercialization of biomaterial products. The company entered into a material definitive agreement with Celularity, Inc. in early 2026 to acquire an exclusive license to Celularity's commercial-stage biomaterials portfolio and related assets. The agreement includes upfront and milestone payments totaling up to $35 million. NexGel has also engaged in private placements issuing convertible notes and warrants to raise capital for business development and to fund the upfront license fee. The company reported a net loss in Q1 2026 but has demonstrated strong revenue growth in prior periods. NexGel's board and executive team include experienced professionals with backgrounds in finance, biotech, and capital markets. The company is currently addressing a Nasdaq listing deficiency due to its stock price falling below the minimum bid price requirement.

Glucotrack, Inc. was incorporated in 2010 and is focused on developing an implantable continuous blood glucose monitor (CBGM) for diabetes patients. The company initially developed a non-invasive glucose monitor but ceased its commercialization in 2023 to focus on the CBGM. The CBGM is designed to be implanted subcutaneously with a lead placed in a blood vessel, enabling continuous glucose measurement with effectively zero lag time compared to existing CGMs that measure interstitial fluid glucose. The company has completed multiple preclinical animal studies demonstrating sensor longevity of at least two years, with modeling supporting three-year longevity. A first-in-human acute study in 2025 showed safety and device performance. A long-term clinical study in Australia was initiated but later closed to focus on a U.S. clinical trial program pending FDA IDE approval. Glucotrack holds ISO 13485 certification and outsources manufacturing to certified contract manufacturers. The company faces competition from established CGM providers and is developing reimbursement strategies. As of March 31, 2026, Glucotrack had limited liquidity and is addressing Nasdaq listing compliance issues.

M3-Brigade Acquisition V Corp. is a Cayman Islands exempted blank check company established to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. The company was formed by executives from M3 Partners and Brigade Capital Management, leveraging their expertise in financial advisory and credit-focused investment strategies. The management team has a track record of organizing multiple SPACs and completing business combinations, including in renewable energy and digital assets sectors. The company completed its IPO in August 2024, raising gross proceeds of $287.5 million, which are held in a trust account invested in U.S. government securities or money market funds. The company has issued Class A and Class B ordinary shares and warrants as part of its capital structure. It has appointed new leadership including CEO Reeve Collins and President Chinh Chu in May 2025. The company is actively pursuing a business combination with ReserveOne, Inc., a Delaware corporation, with detailed merger and domestication steps outlined in the Business Combination Agreement. As of March 31, 2026, the company reported net income for the quarter but has a working capital deficit and low liquidity ratios. The company’s executive offices are located in New York, NY.

Columbus Circle Capital Corp II is a Cayman Islands exempted blank check company incorporated in April 2025. It completed its IPO in February 2026, raising gross proceeds of $230 million plus $6.65 million from a private placement. The company’s purpose is to identify and complete a business combination with one or more businesses or entities within 24 months of the IPO. To date, it has not generated operating revenues or selected a target. The management team has prior SPAC experience and focuses on opportunities in AI, digital infrastructure, sports, media, entertainment, healthcare, energy transition, mining, and cryptocurrency sectors, primarily in EMEA and Latin America. The company’s capital is held in a trust account pending a business combination. It faces dilution risks from founder shares, warrants, and convertible loans, and potential impacts from international trade policies on target selection and post-combination performance.

Cantor Fitzgerald Income Trust, Inc. is a Maryland-based REIT formed to invest in and manage a diversified portfolio of income-producing commercial real estate and multifamily properties, as well as other real estate-related assets primarily in the United States. The company operates through an Operating Partnership and is externally managed by an Advisor, a wholly owned subsidiary of its sponsor, Cantor Fitzgerald Investment. It conducts continuous public offerings of common and preferred stock to raise capital for acquisitions and operations. As of March 31, 2026, the company owned interests in 42 properties including retail, office, industrial, multifamily residential, life sciences, and data center assets across multiple U.S. states. The portfolio is diversified by property type and geography, with a weighted average occupancy of 96.0%. The company uses debt financing within charter limits and relies on proceeds from offerings, financing, and operations to fund its activities. It reported Q1 2026 revenue of approximately $26.6 million and a net loss of $2.5 million, with funds from operations of $2.7 million. The company has no employees and relies on its Advisor for day-to-day management and operations.

FG Imperii Acquisition Corp. is a blank check company incorporated in the Cayman Islands on September 16, 2025. It was formed to pursue a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses in the financial services industry, primarily in North America, but is not limited to any particular industry or geography. The company completed its initial public offering (IPO) in early 2026, issuing 20 million units at $10 per unit, with an over-allotment option exercised for an additional 2.75 million units. The net proceeds from the IPO and related private placements are held in a trust account invested in short-term U.S. Treasury obligations. As of March 31, 2026, the company had not commenced operations and generates income primarily from interest on the trust account. The company’s ability to commence operations depends on completing a business combination meeting Nasdaq and regulatory requirements.

Kochav Defense Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in January 2025 in the Cayman Islands. Its business purpose is to identify and complete a Business Combination with one or more companies, focusing on the defense and aerospace industries. The company completed its IPO in May 2025, raising gross proceeds of $253 million plus $5.24 million from a Private Placement to its Sponsor. The proceeds are held in a Trust Account until a Business Combination is consummated. The company has not yet selected a target and has no operating revenues. Its management team has prior SPAC experience and aims to leverage industry relationships to identify acquisition targets with strong fundamentals, free cash flow potential, competitive advantages, and experienced management. The company must complete its Business Combination by November 29, 2026, or by May 29, 2027, if extended with shareholder approval. The company’s financial snapshot as of March 31, 2026, shows strong liquidity with a current ratio of 4.45. Risks include competition for targets, dilution to shareholders, and the ability to consummate a Business Combination within the required timeframe.

Streamex Corp. transitioned from a medical device technology company to a diversified technology platform focused on tokenized finance and digitization of real-world assets (RWAs) through its acquisition of Streamex Exchange Corporation in May 2025. The company operates a blockchain-based platform enabling issuance, trading, and backend infrastructure for digital tokens backed by physical commodities, starting with gold. The legacy PURE EP™ Platform for cardiac electrophysiology remains part of the business but with limited recent commercial activity. Streamex Exchange was in development stage through 2025 and launched its GLDY token in 2026, beginning to accept subscriptions. The company operates as a single reportable segment and manages consolidated financial performance. As of March 31, 2026, Streamex held $6.86 million in cash and $45.9 million in current assets, with a strong liquidity profile. The company has incurred significant net losses, primarily due to non-cash derivative liabilities and stock-based compensation expenses. Recent capital raises and debt repayments have improved liquidity. Future revenue generation depends on platform maturity, regulatory developments, market adoption, and successful commercialization of tokenized products.

FG Merger II Corp. is a blank check company incorporated in Nevada in September 2023. Its business model centers on identifying and completing a business combination, typically a merger or acquisition, with one or more target companies. The company completed an IPO in January 2025, raising gross proceeds of $80 million, which, along with private placement proceeds, were placed in a trust account to be used primarily for the business combination. The company has not generated operating revenues and has limited operational activity beyond organizational and IPO-related expenses. The company has entered into a merger agreement with Boxabl Inc., which involves a two-step merger process resulting in Boxabl becoming a wholly owned subsidiary and then merging into FG Merger II Corp., which will be renamed Boxabl Inc. Post-merger, the company intends to focus on the financial services industry but is not restricted to any sector or geography. The company maintains Nasdaq listings for its units, common stock, and rights. Management consists of two executive officers who devote variable time until the business combination is completed. The company faces typical SPAC risks including the ability to complete the business combination and retain key personnel.